|
DARS expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.66133814775094E-16 |
| Normal-vs-Stage2 |
4.68380000007151E-07 |
| Normal-vs-Stage3 |
3.26405569239796E-14 |
| Normal-vs-Stage4 |
1.79944947831245E-12 |
| Stage1-vs-Stage2 |
3.922000E-01 |
| Stage1-vs-Stage3 |
6.772400E-02 |
| Stage1-vs-Stage4 |
4.701500E-02 |
| Stage2-vs-Stage3 |
6.695700E-02 |
| Stage2-vs-Stage4 |
3.373600E-02 |
| Stage3-vs-Stage4 |
6.173000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.7256999996238E-07 |
| Normal-vs-Asian |
8.91831053451142E-12 |
| Caucasian-vs-AfricanAmerican |
6.922800E-01 |
| Caucasian-vs-Asian |
9.031200E-01 |
| AfricanAmerican-vs-Asian |
7.643000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.11171138540112E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
9.210400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.63602464908763E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
6.9289018966856E-12 |
| Normal-vs-Age(81-100Yrs) |
1.458190E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.823800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.678400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.017000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.628200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.979590E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.443200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.441400E-01 |
| Classical-VS-Follicular |
2.764500E-03 |
| Classical-VS-Other |
6.469800E-01 |
| Classical-VS-Normal |
1.69164682262135E-12 |
| Tall-VS-Follicular |
4.042100E-03 |
| Tall-VS-Other |
8.932000E-01 |
| Tall-VS-Normal |
1.52010004583758E-09 |
| Follicular-VS-Other |
4.871600E-02 |
| Follicular-VS-Normal |
4.18810000000214E-05 |
| Other-VS-Normal |
4.438600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.42375042048116E-13 |
| Normal-vs-N1 |
6.98330282489223E-14 |
| N0-vs-N1 |
2.456300E-02 |
|
|
